In a genetic association study of 598 Maya-mestizo adults in Yucatán assessed with the MINI 5.0 (DSM-IV), the HTR2C rs2428707 variant was linked to major depression (OR 2.31, 95% CI 1.03–5.18; p=0.041) amid high baseline prevalence (38.9% major depression; 24.7% suicide risk). TPH2 (rs7305115) and BDNF (rs6265) variants were associated with melancholic subtype, while no variant showed a statistically significant association with suicide risk.

Why It Matters To Your Practice

• This understudied Maya-mestizo population has the country’s highest suicide rates, and the study found a measurable genetic signal tied to depression risk.

• High symptom burden in the sample (38.9% major depression) supports a low threshold for screening, especially in rural/underserved settings.

• The finding reinforces that depression phenotypes (e.g., melancholic features) may have differing biological correlates—relevant to assessment and referral decisions.

Clinical Benefits

• Supports more proactive case-finding: routine depression screening and structured diagnostic follow-up (the study used MINI 5.0) in high-risk communities.

• Encourages phenotype-specific documentation (melancholic features, functional status) that can sharpen treatment planning and psychiatric referral.

• Helps frame patient education: depression risk may reflect both sociocultural stressors and biological vulnerability—reducing stigma and supporting engagement.

Managing Risks

• Avoid over-interpreting genetics: an OR of 2.31 indicates increased odds, not determinism; this is not a standalone diagnostic or treatment tool.

• Suicide risk was common (24.7%) but not genetically associated here—so continue standard suicide screening and safety planning regardless of genotype.

• Be cautious generalizing beyond Maya-mestizo adults in Yucatán; ancestry and local context may limit transferability to other populations.

The Bottom Line

• In Maya-mestizo adults, HTR2C rs2428707 was associated with major depression (OR 2.31), highlighting a potential population-specific vulnerability signal.

• For NPs and PAs, the immediate action is clinical: consistent screening, careful phenotype assessment, and robust suicide-risk workflows—not genetic testing.